Latest News
-
Friday - May 29, 2020
Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):
Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer
71% overall response rate (ORR) per investigator assessment and median duration of response of 35.2 months shown in expanded data set of 116 adult patients with TRK fusion cancer / Among patients with brain metastases, ORR was also 71% / Majority of adverse events (AEs) were grade 1 or 2, no new unexpected grade 3 or 4 AEs were reported / New analysis demonstrates clinically meaningful and sustained improvements in quality of life (QoL) in adult and pediatric patients » more
-
Friday - May 29, 2020
Bayer furthers commitment to greater transparency on glyphosate and stakeholder engagement through new dialogue event series
Stakeholders invited to follow virtual EURACTIV conference on June 4 / Company continues to raise the bar on its own transparency standards / Glyphosate Renewal Group (GRG) relaunches its www.glyphosate.eu website » more
-
Tuesday - May 26, 2020
Bayer to support Harvard Research Study to Evaluate Trust in Science, Including in COVID-19 pandemic » more
-
Friday - May 22, 2020
Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer » more
-
Tuesday - May 19, 2020
Nine internationally recognized experts join Sustainability Council
Independent external council to advise Bayer’s Board of Management on consistent implementation of its sustainability targets » more
-
Thursday - May 14, 2020
Not intended for U.S. and UK Media
Bayer and ArcherDX to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) for precision oncology treatment Vitrakvi™
Collaboration focus on development of a companion diagnostic (CDx) for Vitrakvi™ (larotrectinib), the first and only TRK inhibitor approved in Europe for adult and pediatric patients with TRK fusion cancer across all solid tumors / Goal is to advance broad patient access to comprehensive genomic testing through kit-based CDx that can be deployed locally at the site of care in line with Bayer’s commitment to precision medicine » more
-
Wednesday - May 13, 2020
Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
Darolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE) / Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, allowing men with nmCRPC to maintain their active lifestyle / ARAMIS data will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on Friday, May 29, and will be available on the ASCO website » more
-
Monday - May 11, 2020
Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Updated efficacy and safety data for larotrectinib (Vitrakvi™) from an expanded set of adult patients with TRK fusion cancer and a quality of life (QoL) analysis in adult and pediatric patients / New safety and efficacy data from established compounds including radium-223 dichloride (Xofigo™) and regorafenib (Stivarga™) » more
-
Tuesday - April 28, 2020
Online
Annual Stockholders’ Meeting 2020 » more
-
Tuesday - April 28, 2020
CEO Werner Baumann at the Bayer AG Annual Stockholders’ Meeting:
“We’re active in the right businesses”
Coronavirus crisis: Employee safety at the top of the agenda / First DAX company to hold virtual stockholders’ meeting / Strategic and operational targets attained in 2019 / Dividend of 2.80 euros per share proposed / Good start to fiscal 2020 / Winkeljohann to succeed Wenning as Supervisory Board Chairman » more
-
Monday - April 27, 2020
First quarter of 2020:
Bayer: Good start to 2020 – activities marked by COVID-19
Employee safety and business continuity are top priorities / Wide-ranging humanitarian and social engagement / Group sales increase by 6.0 percent (Fx & portfolio adj.) to 12.845 billion euros / EBITDA before special items up by 10.2 percent to 4.391 billion euros / All divisions report higher sales and earnings – strong demand at Consumer Health / Net income advances by 20.0 percent to 1.489 billion euros / Core earnings per share increase by 9.9 percent to 2.67 euros / Outlook for 2020: impact of COVID-19 not yet reliably quantifiable » more
-
Friday - April 24, 2020
Treatment of COVID-19:
Bayer to donate one million tablets of chloroquine for use in Italy
Added by AIFA along with other drugs to the list of medicines for off-label use against COVID-19 » more
-
Thursday - April 23, 2020
Not intended for U.S. and UK Media
Bayer to highlight clinical data on Vitrakvi™ (larotrectinib) and research on investigational AhR inhibitor at AACR 2020 Virtual Meeting
Additional analyses from clinical trials may further aid in identifying the appropriate patients for Vitrakvi™ (larotrectinib), including a presentation on patient outcomes by prior therapy and performance status / Featured research includes an oral presentation in the Plenary Session on efficacy and safety outcomes in patients with NTRK gene fusions or other alterations / Structure and functional characterization of investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor, BAY 2416964, in immunotherapy » more
-
Tuesday - April 21, 2020
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Investigation of combination therapies including Bayer’s chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patients » more
-
Friday - April 17, 2020
Solidarity in the fight against COVID-19:
Bayer to donate EUR 1 million to support the fight against the coronavirus pandemic in France
Money will help caregivers, patients and their families, and fund research / Bayer is supporting various further initiatives in France » more
-
Friday - April 17, 2020
Further emergency aid:
Bayer to donate EUR 1 million to support the fight against COVID-19 in Brazil
Support for projects of the Brazilian government, the national health system and UNICEF » more
-
Tuesday - April 14, 2020
An additional article on fighting the corona pandemic:
Bayer donates 8 million chloroquine tablets to the German Federal Government
Additional donations of chloroquine sent to governments in numerous other countries / Various clinical and preclinical studies investigate the efficacy and adverse effects in COVID-19 infections / Bayer plans considerable expansion of production capacities in the event that the efficacy of chloroquine is proven for COVID-19 » more
-
Wednesday - April 8, 2020
Comprehensive aid package:
Bayer supports fight against the corona pandemic in Spain with measures totaling approximately 1 million euros » more
-
Wednesday - April 8, 2020
Not intended for U.S. and UK Media
Bayer launches pre-filled syringe to administer eye medication Eylea™ in Europe » more
-
Monday - March 30, 2020
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer
Oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profile » more
Copyright @ Bayer AG